SSRI + 5-HT1A partial agonist

Plain-language summaryIntrigue 53 / 100

Vilazodone (Viibryd) is an antidepressant from Forest Pharmaceuticals, approved in 2011, designed to do two things at once: block the serotonin pump like an SSRI and also directly partially activate the 5-HT1A serotonin receptor. The theory was that hitting 5-HT1A directly would short-circuit the slow autoreceptor desensitization process that normally delays SSRI response by several weeks. In practice the speed advantage in trials has been modest, and the drug has not displaced standard SSRIs as a first-line option. It does have somewhat lower rates of sexual dysfunction than SSRIs, which is its main practical selling point. Must be taken with food (at least 500 calories) for adequate absorption. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

50/100

FDA-approved dual-mechanism antidepressant with real pharmacology but limited frontier research appeal

Look, vilazodone is a real drug with a real rationale. The idea behind it is sound: block SERT to raise synaptic serotonin, and simultaneously activate 5-HT1A autoreceptors directly so you dont have to wait weeks for those autoreceptors to desensitize on their own. That delay is one of the genuine frustrations with plain SSRIs, and Forest Pharmaceuticals actually tried to engineer around it. That kind of mechanistic intentionality is worth acknowledging.

The problem is that the clinical payoff was modest. The faster-onset hypothesis showed up in some trial data but hasnt become a defining feature of how clinicians actually use the compound. The PETAL studies and subsequent Phase 3 work confirmed MDD efficacy — theres no question it works — but the differentiation story got muddier after vortioxetine arrived in 2013 with an even broader receptor profile (SERT, 5-HT1A, 5-HT1B, 5-HT3, 5-HT7) and a more compelling case for cognitive symptom improvement. At that point, vilazodone became the simpler version of the multi-target antidepressant concept rather than its leading example.

From a bench perspective, vilazodone does carry real value as a reference probe. If you’re designing experiments to dissect combined SERT inhibition plus 5-HT1A partial agonism — specifically trying to separate those two contributions to a behavioral or molecular endpoint — vilazodone gives you a clean, well-characterized tool with published pharmacokinetics and known receptor affinities (SERT Ki ~0.1 nM, 5-HT1A Ki ~0.2 nM, intrinsic activity ~70%). Thats not nothing. The CYP3A4 metabolism and the food-effect on bioavailability are well-documented, which makes dosing in animal models somewhat more predictable.

What we dont think is that vilazodone represents a current research priority. The antidepressant mechanism space has moved on. The interesting questions now involve psychoplastogens, BDNF-TrkB direct agonism, AMPA potentiation, and neuroinflammatory targets. Vilazodone is an approved drug, which means its evidence base is solid, but solid evidence on a mature mechanism in a saturated class isnt the same as a compelling research target. For investigators specifically studying 5-HT1A partial agonism pharmacology, it remains a useful reference. For everyone else, its a clinical compound that belongs in formularies, not on the short list of compounds worth bench time in 2025.

Honestly, the score of 50 reflects exactly what it is: competent, approved, well-understood, and no longer at the frontier of anything.

Novelty: 28
Mechanism promise: 55
In-category differentiation: 40
Evidence quality: 72
Translational signal: 65
Research bench value: 45

Rationale Vilazodone’s combined SERT + 5-HT1A partial agonism is genuine pharmacological thinking and the rubric explicitly places dual SERT/5-HT1A in the 50-70 mechanism range, but its novelty is low as a 2011-approved drug with mature literature, and vortioxetine has meaningfully outpaced it on multi-receptor differentiation. Strong evidence quality from Phase 3 RCTs props the overall up, but this is not a frontier target.

SSRI + 5-HT1A partial agonist

A dual-mechanism antidepressant combining SSRI activity with 5-HT1A partial agonism intended to accelerate clinical response.

Abstract

Vilazodone (5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide; CAS 163521-12-8; molecular formula C26H27N5O2; molecular weight 441.53) is an SSRI plus 5-HT1A partial agonist developed at Merck KGaA and Forest Pharmaceuticals, approved by the FDA in 2011 under the trade name Viibryd. SERT affinity is approximately 0.1 nM; 5-HT1A affinity is approximately 0.2 nM (intrinsic activity approximately 70 percent), producing partial agonism at the autoreceptor. The dual mechanism was designed to bypass the autoreceptor desensitization period that delays SSRI response: by directly activating 5-HT1A receptors while blocking SERT, vilazodone aims to produce faster clinical effect. Real-world clinical trials have shown modest response acceleration. Plasma half-life is approximately 25 hours; metabolism is via CYP3A4 (primary). Approved for major depressive disorder. The compound is administered with food, which doubles bioavailability compared to fasted dosing. Used as a reference compound for 5-HT1A partial agonist plus SSRI pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-212Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: SSRI + 5-HT1A partial agonist

Vilazodone

Abstract

Read the full monograph